A community-based trial has demonstrated that HPV self-sampling increases screening amongst groups of Māori, Pacific and Asian women in New Zealand. The study included 3553 never- and markedly under-screened (≥5 years overdue) women aged 30-69 years. Women were randomised to clinic-based self-sampling (n = 1574), home-based self-sampling (n = 1467), or usual care (invited to attend a clinic for collection of a standard cytology sample; n = 512). Participation was highest for home-based self-sampling (14.6% in Māori, 8.8% in Pacific, and 18.5% in Asian women). Corresponding rates for clinic-based self-sampling were 7.0%, 5.3% and 6.9%, respectively. Participation rates for usual care were only 2.0%, 1.7% and 4.5%, respectively. The adjusted odds ratio for participation in home-based self-sampling vs usual care was 9.7 (95% CI 3.0-31.5) for Māori women, 6.0 (95% CI 1.8-19.5) for Pacific women, and 5.1 (95% CI 2.4-10.9) for Asian women. No adverse outcomes were reported. Non-responding women were invited to participate in a follow-on substudy after 3 months. Of these women, 192/2780 (6.9%) had taken an HPV self-sample by 6 months.
